Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease - PubMed

Review

Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease

Dileep K Vijayan et al. Pharmacol Res. 2019 Sep.

Abstract

Human glutaminyl cyclase (hQC) is an important enzyme for post-translational modification by converting the N-terminal glutaminyl and glutamyl into pyroglutamate (pGlu) through cyclization. The two isoforms of hQC, secretory glutaminyl cyclase (sQC) and golgi resident glutaminyl cyclase (gQC), are involved in various pathological conditions especially in Alzheimer's disease (AD). The sQC is known to mediate the formation of pyroglutamate containing amyloid beta (pGlu-Aβ) peptides while gQC mediates the maturation of C-C motif chemokine ligand 2 (CCL2). Therefore, hQC (both sQC and gQC) inhibition is considered to be an attractive strategy to prevent the formation of pGlu-Aβ and to reduce neuroinflammation and hence provides a new opportunity for the treatment of AD. In this review, we summarize our current understanding on the structure, function and inhibitors of hQC and its involvement in Alzheimer's disease.

Keywords: Alzheimer’s disease; CCL2; Golgi resident glutaminyl cyclase; Human glutaminyl cyclase; Pyroglutamate; Secretory glutaminyl cyclase; pGlu-Aβ peptide.

Similar articles

• Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.

  Chandran R, Dileep KV. Chandran R, et al. Chem Biol Drug Des. 2021 Nov;98(5):850-856. doi: 10.1111/cbdd.13940. Epub 2021 Sep 15. Chem Biol Drug Des. 2021. PMID: 34423556

• Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.

  Huang KF, Liaw SS, Huang WL, Chia CY, Lo YC, Chen YL, Wang AH. Huang KF, et al. J Biol Chem. 2011 Apr 8;286(14):12439-49. doi: 10.1074/jbc.M110.208595. Epub 2011 Feb 1. J Biol Chem. 2011. PMID: 21288892 Free PMC article.

• Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.

  Zhang Y, Wang Y, Zhao Z, Peng W, Wang P, Xu X, Zhao C. Zhang Y, et al. Eur J Pharmacol. 2022 Sep 15;931:175178. doi: 10.1016/j.ejphar.2022.175178. Epub 2022 Aug 7. Eur J Pharmacol. 2022. PMID: 35948163 Review.

• The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders.

  Pozzi C, Di Pisa F, Benvenuti M, Mangani S. Pozzi C, et al. J Biol Inorg Chem. 2018 Dec;23(8):1219-1226. doi: 10.1007/s00775-018-1605-1. Epub 2018 Aug 21. J Biol Inorg Chem. 2018. PMID: 30132075

• An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.

  Coimbra JR, Sobral PJ, Santos AE, Moreira PI, Salvador JA. Coimbra JR, et al. Future Med Chem. 2019 Dec;11(24):3179-3194. doi: 10.4155/fmc-2019-0163. Future Med Chem. 2019. PMID: 31838899 Review.

Cited by

• Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications.

  Li Q, Zhang Z, Fan Y, Zhang Q. Li Q, et al. Front Genet. 2021 Jan 12;11:562868. doi: 10.3389/fgene.2020.562868. eCollection 2020. Front Genet. 2021. PMID: 33510766 Free PMC article. Review.

• 2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.

  Park E, Song KH, Kim D, Lee M, Van Manh N, Kim H, Hong KB, Lee J, Song JY, Kang S. Park E, et al. ACS Med Chem Lett. 2022 Aug 16;13(9):1459-1467. doi: 10.1021/acsmedchemlett.2c00256. eCollection 2022 Sep 8. ACS Med Chem Lett. 2022. PMID: 36105338 Free PMC article.

• Role of glutaminyl-peptide cyclotransferase in breast cancer doxorubicin sensitivity.

  Xu B, Yang L, Yang L, Al-Maamari A, Zhang J, Song H, Wang M, Su S, Song Z. Xu B, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2321767. doi: 10.1080/15384047.2024.2321767. Epub 2024 Feb 28. Cancer Biol Ther. 2024. PMID: 38417050 Free PMC article.

• Review on anti-alzheimer drug development: approaches, challenges and perspectives.

  Abdallah AE. Abdallah AE. RSC Adv. 2024 Apr 5;14(16):11057-11088. doi: 10.1039/d3ra08333k. eCollection 2024 Apr 3. RSC Adv. 2024. PMID: 38586442 Free PMC article. Review.

• Advances in Alzheimer's disease's pharmacological treatment.

  Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Conti Filho CE, et al. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023. Front Pharmacol. 2023. PMID: 36817126 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information